جست‌وجوی استاد و پژوهشگر

Paul Midgleyمشاهده پروفایل

استاد

• Electron Microscopy
• 3D Imaging
• Nanomaterials
• +۴ مورد دیگر

Paul Midgley is the Professor of Materials Science at the University of Cambridge , affiliated with the Department of Materials Science & Metallurgy . His research focuses on advancing electron microscopy techniques for nanoscale structural analysis. BSc, MSc, PhD from the University of Bristol Research Interests: Development of 3D electron tomography, precession electron diffraction (PED), and multi-dimensional imaging techniques to study materials at atomic and nanoscale resolutions. Applications span semiconductor nanowires, catalysts, pharmaceuticals, and metal-organic frameworks (MOFs). Notable Trends: Recent work emphasizes nanoscale heterogeneities in halide perovskites, mechanochemical amorphisation of MOFs, and structural analysis of pharmaceutical formulations using 3D electron diffraction. Collaborations integrate machine learning and advanced reconstruction algorithms. Scientific Awards: Fellow of the Royal Society (FRS) Honorary Fellow of the Royal Microscopical Society (HonFRMS) MAE (Materials Ageing and Environment) Award Labs & Teams: Leads the Electron Microscopy Group at Cambridge. Research involves dual beam SEM-FIB, EDX, and EBSD techniques for mesoscale tomography. Collaborates with institutions in the UK, Europe, and globally.

• Analytical Chemistry
• Electrochemical Sensors
• Flow Injection Analysis
• +۲ مورد دیگر

Aleksandar D. Lolić is a Full Professor in the Department of Analytical Chemistry at the Faculty of Chemistry, University of Belgrade, where he has served since 2003. His career progression includes Assistant Trainee (2003-2007), Assistant (2007-2014), Assistant Professor (2014-2019), Associate Professor (2019-2024), and Full Professor (2024-present). He actively contributes to academic governance as a member of the Faculty Council and enrollment committees. His educational background: Undergraduate studies in Chemical Sciences, University of Belgrade - Faculty of Chemistry (1991-1999) Master's degree in Chemical Sciences, same institution (2000-2006) Doctorate in Chemical Sciences (2008-2012) Dr. Lolić's research centers on developing electrochemical sensors and flow injection analysis methods for environmental and pharmaceutical applications. His work emphasizes pollutant detection in complex matrices, active pharmaceutical substance analysis, and biologically active compound investigation. Key methodologies include amperometric detection, modified electrodes, and advanced flow systems for sensitive quantification of contaminants. His publication trends (2021-2023) reveal concentrated efforts in environmental toxicology and pharmaceutical electroanalysis. Recent work addresses heavy metal risks in soil/water/cosmetics, ibuprofen detection via polyglycine-modified electrodes, and ascorbic acid sensing using composite materials. These studies consistently employ flow injection systems coupled with electrochemical detection for real-sample analysis. No scientific awards are documented in the available information. He participates in significant research initiatives including the active Horizon 2020 project IMPTOX (2021-2025) investigating micro/nano-plastics and environmental pollutants' impact on allergic disease risks. Previously, he contributed to a national fundamental project (2011) developing electrochemical/flow methods for environmental monitoring. His teaching portfolio includes Analytical Chemistry 2, Flow Methods in Analytical Chemistry, and Modern Instrumental Methods. He leads the Research Group for Development and Application of Analytical Sensors and Investigation of Biologically Active Compounds, focusing on electrochemical sensor innovation and flow injection system optimization within the Department of Analytical Chemistry laboratories.

Molly S. Shoichetمشاهده پروفایل

استاد

• Tissue Engineering
• Regenerative Medicine
• Drug Delivery
• +۴ مورد دیگر

Molly S. Shoichet serves as a University Professor at the University of Toronto's Faculty of Applied Science and Engineering, holding the Pamela and Paul Austin Chair in Precision and Regenerative Medicine and previously the Michael E. Charles Chair in Chemical Engineering. She leads the Shoichet Laboratory (Room 514, 160 College Street) focused on biomaterials-driven solutions for regenerative medicine and drug delivery challenges. Her educational foundation includes a B.Sc. from MIT and M.Sc./Ph.D. from the University of Massachusetts. This training underpins her cross-disciplinary approach integrating engineering, chemistry, and biology to address unmet medical needs. Shoichet's research centers on four synergistic pillars: (1) Targeted cancer delivery using colloidal drug aggregates for breast, brain, lung, and lymphoma; (2) Injectable hydrogels enabling sustained biomolecule release to the CNS for spinal cord/retinal repair; (3) 3D biomimetic scaffolds modeling disease microenvironments for drug screening; and (4) Cell delivery systems enhancing stem cell survival in blindness/stroke applications. Her lab emphasizes translational impact through commercialization efforts like AmacaThera. Analysis of her 2021-2025 publications reveals accelerating innovation in RNA delivery platforms, neural repair strategies, and disease-specific hydrogel systems, with strong emphasis on pulmonary delivery, stroke recovery mechanisms, and ocular therapeutics. These works bridge nanomedicine, regenerative biology, and clinical translation across cancer and neurological disorders. Her exceptional contributions are recognized through over 30 major honors including: Gerhard Herzberg Canada Gold Medal (2020) Killam Prize in Engineering (2017) Foreign Membership in US National Academy of Engineering (2016) Fellowship in The Royal Society (2019) Officer of the Order of Canada (2018) L’Oréal-UNESCO For Women in Science Laureate (2015) Shoichet actively mentors graduate students (including OGS/QEII scholars Chris Ling, Nadiyah Khan, and Riley Li) and secures major funding from Natural Sciences and Engineering Research Council (NSERC), Canadian Institutes of Health Research (CIHR), Canada First Research Excellence Fund (Medicine by Design), Krembil Foundation, and McEwen Foundation. Her lab operates as a multidisciplinary hub collaborating with stem cell biologists, neurosurgeons, and cancer researchers to advance therapeutic pipelines. The Shoichet Lab maintains state-of-the-art facilities for polymer synthesis, cell culture, and in vivo testing, with current projects focused on RNA delivery stabilization, glaucoma treatment systems, and stroke recovery mechanisms. Her TERMIS-Americas leadership and commercialization initiatives demonstrate commitment to translating biomaterials innovations into clinical impact.

Martina Kerscherمشاهده پروفایل

استاد

• Dermatocosmetics
• Skin Physiology and Pathology
• Aesthetic Medicine
• +۳ مورد دیگر

Prof. Dr. Martina Kerscher is a faculty member at the University of Hamburg, leading the AG Kerscher working group within the Department of Chemistry under the Institute of Biochemistry and Molecular Biology. Her research focuses on dermatocosmetics, skin aging, and clinical evaluation of aesthetic treatments. Habilitation at Ruhr-University Bochum (1996) Head of the Cosmetic Science program at University of Hamburg (2000–present) Active in GCP-certified clinical trials (Phase Ib–IV) for over 20 years Author of books like "Dermatokosmetik" and "Haut und Alter" Her research spans intrinsic and extrinsic factors affecting skin physiology, in-vivo drug testing for anti-aging, acne, and hair loss, and the impact of minimally invasive procedures. Recent publications emphasize validated photonumeric scales for aesthetic assessments and hyaluronic acid applications. Collaborations include European and international teams in aesthetic medicine, with a focus on regenerative treatments like blood cell secretome and cohesive polydensified matrix fillers. She has contributed extensively to clinical guidelines and consensus practices in aesthetic dermatology. AG Kerscher offers opportunities for doctoral and master’s students in clinical and dermatological research. The group participates in cutting-edge studies for soft tissue augmentation and skin revitalization.

Christopher J. Cooperمشاهده پروفایل

استاد

• Cardiovascular Medicine
• Interventional Cardiology
• Renovascular Hypertension
• +۴ مورد دیگر

Christopher J. Cooper, M.D., is Distinguished University Professor of Medicine at the University of Toledo, Ohio, where he also served as Dean of the College of Medicine (2014-2024), CEO of University of Toledo Physicians, and Executive Vice-President for Clinical Affairs. Triple-board-certified in Internal Medicine, Cardiovascular Disease, and Interventional Cardiology, he directs the UT Clinical Coordinating Center and has led national randomized trials on renal-artery stenosis. Education & Training: B.A. magna cum laude in Biology (Philosophy minor), Wittenberg University, 1985 M.D., University of Cincinnati College of Medicine, 1988 — Valedictorian, Alpha Omega Alpha Internship & Residency, Brigham and Women’s Hospital / Harvard Medical School, 1988-1991 Cardiology Fellowship, Brigham and Women’s Hospital, 1991-1994 Harvard School of Public Health, Clinical Effectiveness Program, 1992 Research Focus: Cooper’s group investigates renovascular hypertension, renal-artery stenosis, and cell-based therapies for vascular disease. As PI of the NIH-funded CORAL trial and multiple industry grants, he has published pivotal papers defining when renal stenting benefits patients and elucidating inflammatory and signaling pathways that couple renal artery narrowing to hypertension and renal failure. Recent work integrates large-scale clinical outcomes databases with mechanistic studies on Na/K-ATPase signaling, microRNA regulation of cardiac fibrosis, and biomarkers such as CD40-ligand in renovascular disease. Honors & Awards: Best Doctors in America — multiple years (2002-2014) America’s Top Doctors, Castle Connolly — consecutive listings (2006-2015) College of Medicine Award for Excellence in Clinical Research, UT (2008) Elected Fellow, American Heart Association Council on High Blood Pressure Research (2004) Valedictorian & Alpha Omega Alpha, Univ. of Cincinnati (1988) Leadership & Grants: Cooper has held continuous NIH and industry funding for multicenter trials; he founded and directs the UT Clinical Coordinating Center, overseeing regulatory, data, and biostatistical cores for national studies. His administrative leadership spans Department Chair, Heart & Vascular Center Director, and Dean of the College of Medicine, while maintaining an active interventional cardiology practice. Laboratory & Teams: He leads the Cooper Renal & Vascular Research Group within the UT Cardiovascular Research Institute, mentoring faculty, fellows, and graduate students in translational protocols that bridge molecular cardiology, interventional imaging, and large pragmatic trials.

Leonid Chernyakمشاهده پروفایل

استاد

• Semiconductor Physics
• Wide Bandgap Semiconductors
• Electron Transport
• +۶ مورد دیگر

Leonid Chernyak is a Professor in the Department of Physics at the University of Central Florida's College of Sciences. He received his PhD in Physics from Weizmann Institute of Science (Israel) in 1996 and joined UCF in 1999 after spending a year as a Research Associate at Colorado State University and Texas Tech University. Dr. Chernyak's research focuses on semiconductor physics, particularly wide bandgap semiconductors including Gallium Nitride (GaN), Zinc Oxide (ZnO), and Gallium Oxide (Ga2O3). His work centers on electron transport phenomena, radiation effects on semiconductors, and device characterization using techniques like electron beam induced current (EBIC) and cathodoluminescence. His research has significant applications in radiation-hardened electronics, power devices, and optoelectronics. His publication record shows a consistent research trajectory with over 100 publications spanning more than two decades, with recent work focusing increasingly on Ga2O3 as a promising ultra-wide bandgap semiconductor for next-generation power electronics. His articles demonstrate expertise in characterizing radiation damage and developing mitigation strategies through electron injection techniques. Scientific Awards 7 National Science Foundation Awards (2002-2021) 2 American Chemical Society Awards (2002-2021) 7 NATO Awards (2002-2021) 3 US-Israel Binational Science Foundation Awards (2002-2021) 3 Israel Ministry of Defense Awards (2002-2021) University of Central Florida Research Incentive Award (2004, 2015, 2021) Senior Member, Institute of Electrical and Electronics Engineers (IEEE) (1999) Minerva Award of German-Israeli Scientific Foundation (1992) Dr. Chernyak has served as a reviewer for numerous funding agencies, with 15 invitations to NSF panel reviews and 3 invitations to NATO panels between 2001-2020. His work has been recognized with an h-index of 28, and he has been included in various editions of Who's Who in America and Who's Who in Science and Engineering. His research has secured approximately $6 million in funding, demonstrating significant external recognition of his work's importance. He has also contributed 7 book chapters to the field, further establishing his expertise in semiconductor physics and materials characterization.

Jeffrey DeSimoneمشاهده پروفایل

استاد

• Public Policy Analysis
• Health Economics
• Crime and Economics
• +۴ مورد دیگر

Jeffrey DeSimone is a Professor of the Practice of Economics and Director of the Duke Economic Analytics Lab (DEAL) at Duke University's Trinity College of Arts & Sciences since 2022. He holds a Ph.D. in Economics from Yale University (1998). His research focuses on policy evaluation, particularly examining impacts of legal age restrictions on alcohol/tobacco use, gun control legislation, mental health outcomes linked to social security policies, and socioeconomic factors influencing crime and public health. Notable projects include studying suicide rate reductions tied to retirement age policies and analyzing the efficacy of child access prevention laws for reducing gun injuries. DeSimone has taught courses in econometrics, data science, and independent research at Duke, and previously held academic positions at institutions like the University of South Florida, University of Maryland, and University of Iowa. His work combines econometric rigor with real-world policy applications, addressing issues like substance abuse economics, labor market disparities after trauma, and institutional behaviors in higher education settings. His research portfolio includes over 20 peer-reviewed articles in journals such as the American Economic Review, Contemporary Economic Policy, and Journal of Health Economics. While no specific grants or awards are listed, his work demonstrates significant contributions to applied economics with direct policy relevance. The DEAL lab under his direction focuses on innovative analytical approaches to pressing social and economic questions.

Hao Louمشاهده پروفایل

استادیار

• Pharmaceutical Formulations
• Computational Modeling
• Molecular Dynamics
• +۵ مورد دیگر

Dr. Hao Lou is an Assistant Professor in the Department of Pharmaceutical Chemistry at the University of Kansas School of Pharmacy. His research integrates computational modeling and experimental approaches to advance drug formulation design, with emphasis on subcutaneous delivery systems for biologics and oral formulations. Research focuses on: Computational pharmaceutics using machine learning and molecular dynamics Subcutaneous delivery of monoclonal antibodies and protein therapeutics In vitro emulation of subcutaneous absorption (ESCAR system) Formulation optimization for cyclic peptides and biologics Protein stabilization and drying techniques Recent publications demonstrate novel applications of molecular dynamics simulations in predicting peptide properties, optimizing high-concentration protein formulations, and developing biorelevant dissolution methods. Work appears in pharmaceutical sciences journals covering formulation design and computational modeling. Developed innovative platforms including an Emulator of Subcutaneous Absorption and Release (ESCAR) and protein-hyaluronic acid precipitation techniques. Contributes to advancing dry powder processing for inhaled formulations.

Kevin McHughمشاهده پروفایل

استادیار

• Biomaterials
• Biofabrication
• Drug Delivery
• +۶ مورد دیگر

Kevin McHugh is an Assistant Professor of Bioengineering at Rice University and a CPRIT Scholar in Cancer Research. He leads the McHugh Lab, which focuses on developing biomaterial microdevices for drug delivery, cancer immunotherapy, and tissue engineering using advanced fabrication techniques like multi-photon 3D printing. His work bridges materials science, immunology, and global health, with a particular emphasis on single-injection vaccines and controlled-release systems. Education Ph.D., Biomedical Engineering, Boston University (2014) M.S., Biomedical Engineering, Boston University (2012) B.S., Biomedical Engineering, Case Western Reserve University (2009) Research Interests McHugh’s lab explores three core areas: Drug Delivery: Designing systems for targeted drug release to improve vaccine efficacy and chronic disease management. Cancer Immunotherapy: Developing localized immunostimulatory therapies to enhance anti-tumor responses. Tissue Engineering: Creating bioinstructive scaffolds for functional tissue regeneration. Recent projects include a $2M CPRIT grant for cancer immunotherapy and Gates Foundation funding to develop combination vaccines for the developing world. Grants & Awards CPRIT Scholar in Cancer Research NIH R21 Award (2024) NIH R25 Award (2024) Gates Foundation Grant (2024) Lab & Collaborations The McHugh Lab collaborates on translational research, with a focus on clinical feasibility. Notable achievements include microneedle-based vaccination record systems and heat-stable vaccine microparticles. The lab actively trains students in bioengineering, materials science, and immunology.

Louisa Jane Degenhardtمشاهده پروفایل

استاد

• Epidemiology
• Illicit Drug Use
• Mental Health Comorbidity
• +۵ مورد دیگر

Scientia Professor Louisa Jane Degenhardt is a leading epidemiologist at the University of New South Wales (UNSW) , serving as Deputy Director of the National Drug and Alcohol Research Centre (NDARC) within the Faculty of Medicine. She holds honorary Professorial appointments at the University of Melbourne’s School of Population and Global Health, Murdoch Children’s Research Institute, and University of Washington’s Institute of Health Metrics and Evaluation. PhD in epidemiology (2003), focusing on drug use and mental disorder comorbidity in Australia Over 560 peer-reviewed papers, 120 technical reports, three books, and 45 book chapters H-index: 80 (Scopus), 104 (Google Scholar) Her research spans illicit drug epidemiology, comorbid mental health issues, and surveillance systems. She leads studies on opioid antagonist treatment mortality, pharmaceutical opioid use in chronic pain (POINT cohort), and gene-environment interactions in addiction. She also investigates risk behaviors in youth through local/national cohort studies. Louisa has chaired the Secretariat for the UN Reference Group on Injecting Drug Use and HIV (2007–2010) and co-chaired the Expert Group for mental disorders and illicit drug use in the 2010 Global Burden of Disease study. Her work includes indirect prevalence estimation, data linkage studies, and international drug use epidemiology. Scientific Awards: UNSW Scientia Professor NHMRC Senior Principal Research Fellow She contributes to the Drug Trends program at NDARC (rejoining in 2018) and collaborates with WHO/UNAIDS on global drug use risks. Her methodological expertise includes case-control studies, cohort analysis, and policy-relevant research.

Anne Seidlitzمشاهده پروفایل

استاد

• Pharmaceutical Technology
• Biopharmaceutics
• 3D Printing in Drug Delivery
• +۳ مورد دیگر

Anne Seidlitz is a Professor of Pharmaceutical Technology at the Free University of Berlin since October 2024, previously holding the same position at Heinrich Heine University Düsseldorf (2021-2024). Affiliated with the Institute of Pharmacy , she leads the Seidlitz Pharmaceutical Technology Group , focusing on solid dosage forms and biorelevant drug release studies using 3D printing and hydrogel compartments . Doctorate in Pharmaceutical Technology (Greifswald, 2009) Habilitation in Natural Sciences (Greifswald, 2015) Qualified Person under German Medicines Act (AMG) Visiting Professorships: Hamburg, Jena Research Interests: Formulation development for implants , intravitreal injections , and subcutaneous delivery systems , with emphasis on biorelevant dissolution testing under physiological flow/movement conditions. Her group pioneers 3D-printed drug delivery devices and custom hydrogel models for vitreal , ear canal , and vascular implants . Publication Trends: Recent articles focus on thermal stability of steroids during extrusion, individualized implant design , and hydrogel compartments for non-oral dissolution testing . Key collaborations include EUFEPS Network and APV (Association for Pharmaceutical Process Engineering). Scientific Involvement: Member of EUFEPS Network on Bioavailability Scientific Council, German Federal Chamber of Pharmacists Active in APV (Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik) Student Supervision: Mentored 24+ theses including 3D-printed tablets , implant coatings , and vitreal drug distribution . Collaborates with institutions in Düsseldorf , Jena , and Hamburg .

• Substance Use and Addiction
• HIV/AIDS Prevention
• Viral Hepatitis Transmission
• +۵ مورد دیگر

Robert Heimer is a Professor of Epidemiology (Microbial Diseases) and Pharmacology at Yale University, with affiliations to the Yale School of Public Health , Center for Interdisciplinary Research on AIDS (CIRA) , and Yale Institute for Global Health . His research focuses on substance use epidemiology , HIV and viral hepatitis prevention , and harm reduction strategies , particularly addressing the opioid crisis through interdisciplinary methods combining laboratory, behavioral, and structural analyses. PhD in Molecular Biology/Pharmacology (Yale University, 1988) BA in Molecular Biology (Columbia College, 1974) His work examines injection drug use consequences , syringe exchange programs , overdose prevention , and pharmacological addiction treatment , with funding from NIH, CDC, and Gilead Foundation. Recent publications analyze spatial overdose patterns , opioid treatment accessibility , and structural stigma in rural healthcare . He has contributed to understanding HIV transmission in Russia and global harm reduction policy . Scientific Awards: Recognized through Annual Research Awards and Career Achievement Awards at Yale School of Public Health. Dr. Heimer directs the Interdisciplinary Research Methods Core at CIRA and conducts fieldwork in Vietnam and Lebanon, addressing cross-border substance use challenges and stigma in marginalized populations . His research informs public health policy and prison-to-community healthcare transitions .

Mauro Ferrariمشاهده پروفایل

استاد

• Cancer therapeutics
• Nanomedicine
• Drug delivery technology
• +۲ مورد دیگر

Mauro Ferrari is a distinguished Professor in the Department of Pharmaceutics at the University of Washington , joining in 2019. Previously, he served as tenured professor in engineering and/or medicine at institutions including the University of Texas, University of California Berkeley, Ohio State University, and Weill Cornell Medicine. He led the Houston Methodist Research Institute as President & CEO and held leadership roles at the European Research Council. Dottore in Matematica, Universita di Padova, Italy PhD and MS in Mechanical Engineering, University of California, Berkeley Executive education at Harvard Business School and Wharton As a pioneer of nanomedicine and transport oncophysics, his research focuses on cancer therapeutics , nanomedicine , drug delivery technology , mathematical oncology , and biological mass transport . His laboratory leads a DOD-funded initiative for metastatic breast cancer cures. His selected publications highlight trends in nanoparticle design , molecular transport , cancer nanotherapy , and multistage delivery systems . Scientific leadership includes clinical translation of dozens of drugs and medical devices . Current entrepreneurial roles: CEO of DXT Pharmaceuticals, Director at Arrowhead Pharmaceuticals, and Scientific Founder of BrYet US.

• Criminology
• Public Health Policy
• Substance Use Research
• +۵ مورد دیگر

Professor Fiona Measham holds the Chair in Criminology at the University of Liverpool since 2019. Her interdisciplinary research focuses on transgressive leisure, psychoactive substances, and harm reduction, with a particular emphasis on drug policy, nightlife cultures, and gender studies. She has pioneered community-based drug checking services through her role as founder of The Loop, a non-profit NGO operational in the UK and Australia since 2013. Her professional activities include membership in drug policy reform panels (Labour Party, Conservative Party), the ACMD Technical Committee, and Drug Science's Medical Psychedelics and Supervised Injecting Facilities Working Groups. Research interests span drug markets, substance use epidemiology, nightlife safety, and the intersection of gender with criminal justice systems. She has secured significant grants, including a £DEPARTMENT OF HEALTH & SOCIAL CARE (UK) project analyzing youth substance use trends (2021–2023). Teaching responsibilities include convening the SOCI 339 'Drugs, Crime & Society' module, emphasizing critical analysis of drug policy and health sciences. Key contributions include evaluating drug checking efficacy, analyzing festival drug use patterns, and addressing gender-based violence in nightlife settings. Her work bridges academic research with policy advocacy, evidenced by her involvement in UK drug strategy reviews, Scottish drug checking implementation studies, and global harm reduction initiatives.

Roberto Abadieمشاهده پروفایل

استادیار

• Medical Anthropology
• Health Inequalities
• Research Ethics
• +۵ مورد دیگر

Roberto Abadie is an Assistant Professor at the University of Wisconsin-Madison School of Education, specializing in medical anthropology with a focus on health inequalities and social stratification. His research examines marginalized populations, particularly people who inject drugs (PWID), and addresses ethical issues in public health and clinical trials. Abadie holds a Ph.D. in Anthropology from the Graduate Center, CUNY, and completed a postdoctoral fellowship in bioethics at the Mayo Clinic. His work is funded by the NIH/NIDA and the Greenwall Foundation. His research interests include: Health disparities in marginalized communities Research ethics and participant protection Social determinants of HIV/HCV epidemics Drug policy and harm reduction strategies Abadie’s publications highlight the intersections of substance use, public health crises, and structural inequities. His award-winning book *The Professional Guinea Pig* critiques the exploitation of research participants in clinical trials. Key awards: Best Book of the Year Award (Medical Sociology Section, British Sociological Association) His work has informed grants and policy recommendations on opioid use disorder treatment, fentanyl-related risks, and post-disaster health systems in Puerto Rico. He advocates for ethical research practices and equitable healthcare access.